European Medicines Agency accepts for review Marketing Authorization Application for investigational 20-valent pneumococcal conjugate vaccine (20vPnC) for use in adults

Pfizer’s vaccine candidate includes capsular polysaccharide conjugates for the 13 serotypes in Prevenar 13 and also contains capsular polysaccharide conjugates for 7 additional serotypes that cause invasive pneumococcal disease & have been associated with high case-fatality rates

Biospace Inc.